Home | Welcome to Contract Pharma   
Last Updated Sunday, September 21 2014
Print

Teva, Lonza JV Cool On Biosimilars



Published April 5, 2013
Teva and Lonza are re-evaluating the potential of their joint venture to develop, manufacture and market biosimilars. The companies are exploring the best routes to realizing the benefits of biosimilars for certain biologics. With regulatory uncertainty in the biosimilars arena, both companies are taking a measured approach to fully evaluate regulatory and commercial circumstances before agreeing on further long-term investments.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On